Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 546
interventional 475
Observational 66
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 214
Drug|Other 31
Biological 30
Biological|Drug 24
Drug|Radiation 20
Drug|Procedure 19
Biological|Drug|Other 15
Drug|Procedure|Radiation 11
Procedure 11
Biological|Drug|Radiation 10
Biological|Other 10
Other 10
Biological|Drug|Procedure|Radiation 9
Drug|Other|Procedure|Radiation 7
Biological|Drug|Other|Procedure|Radiation 6
Biological|Drug|Other|Procedure 5
Drug|placebo 5
Device 4
Drug|Other|Procedure 3
Drug|Genetic|Other 2
Drug|Other|Radiation 2
Other|Procedure 2
Radiation 2
Behavioral 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Device|Drug|Radiation 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Other|placebo 1
Biological|Drug|Other|Radiation 1
Biological|Drug|placebo 1
Biological|Drug|Procedure 1
Biological|Other|placebo 1
Biological|Other|Procedure 1
Biological|Procedure 1
Biological|Procedure|Radiation 1
Device|Drug|Procedure 1
Diagnostic Test 1
Diagnostic Test|Drug|Procedure 1
Dietary Supplement|Drug 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Genetic 1
Genetic|Radiation 1
Other|placebo 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 299
Germany 23
China 15
NA 14
Italy 11
United States|Canada 9
France 8
United Kingdom 6
Belgium|France 5
Canada 5
United States|Italy 5
Israel 4
Russian Federation 4
United States|Germany 4
Australia 3
Spain 3
United States|Germany|Italy 3
Germany|United Kingdom 2
Netherlands 2
Saudi Arabia 2
United States|Australia|Canada 2
United States|France 2
Argentina 1
Australia|Austria|Belgium|Czechia|Denmark|France|Germany|Ireland|Israel|Italy|Netherlands|New Zealand|Norway|Poland|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
Belgium 1
Belgium|Croatia|Denmark|Egypt|Netherlands|Poland|Portugal|Slovakia|Spain 1
Belgium|Lithuania|Spain 1
Canada|Italy|United Kingdom 1
Czech Republic 1
Czech Republic|Poland|Romania 1
Czechia|Germany|Malaysia|Poland|Spain|Thailand|Turkey 1
Finland 1
France|Germany 1
Germany|Switzerland 1
India 1
Korea, Republic of 1
Netherlands|Belgium|Croatia|Denmark|France 1
Poland 1
Poland|United States|Australia|Belgium|Brazil|Canada|Czechia|Denmark|France|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Norway|Russian Federation|South Africa|Spain|Taiwan|Turkey|United Kingdom 1
Singapore 1
Spain|France|Germany|Italy|Netherlands|Sweden|United Kingdom 1
Taiwan 1
United States|Australia|Belgium|Brazil|Canada|France|Germany|Israel|Italy|Netherlands|New Zealand|Poland|Russian Federation|Singapore 1
United States|Australia|Belgium|Brazil|France|Germany|Israel|Italy|Malaysia|New Zealand|Singapore|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Hong Kong|Italy|Korea, Republic of|Singapore|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Italy 1
United States|Australia|Canada|Israel|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|France|Greece|Hong Kong|Poland|Russian Federation|Singapore 1
United States|Austria|Belgium|Canada|Czechia|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy 1
United States|Belgium|Canada|France|Italy|Spain|United Kingdom 1
United States|Brazil|Hong Kong|Italy|Japan|Singapore|Taiwan 1
United States|Bulgaria|Czechia|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Serbia|Spain|United Kingdom 1
United States|Canada|Czechia|France|Germany|Ireland|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Canada|Puerto Rico 1
United States|Canada|Switzerland 1
United States|Colombia|Czechia|France|Germany|Guatemala|Italy|Korea, Republic of|Spain 1
United States|Denmark|Germany 1
United States|France|Germany|Italy|Mexico|Netherlands|Spain|United Kingdom 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|Hungary|Israel|Italy|Spain 1
United States|Japan|Puerto Rico 1
United States|Puerto Rico 1
United States|Russian Federation 1
United States|Spain 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 242
2 53
3 13
4 14
5 19
6 17
7 8
8 4
9 5
10 10
11 9
12 5
13 5
14 3
15 3
16 2
17 4
18 3
19 2
20 2
21 1
22 5
23 1
25 4
26 2
27 3
28 2
30 2
31 1
35 1
37 1
38 2
39 2
40 2
46 1
47 1
50 1
51 1
54 1
55 2
56 1
62 1
63 1
65 1
87 1
95 1
96 1
106 1
116 1
118 1
175 1
199 1
216 1
410 1
423 1
520 1

Phase

Phase Study_Count
Phase 2 212
Phase 1 97
Phase 1/Phase 2 70
N/A 44
Phase 3 41
Early Phase 1 4
Phase 4 4
Phase 2/Phase 3 3

Number of Arms

Number_of_Arms Count_of_Studies
1 275
2 106
3 24
4 11
5 3
6 4
7 4
8 1
9 2
11 1
NA 44

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00 5.0000 2.00000 6.00000 1.00000 101.0000 6.000 60
1st Qu. 9.00 20.7500 17.50000 30.00000 29.25000 135.0000 240.000 165
Median 18.00 58.5000 30.00000 46.00000 50.00000 169.0000 340.000 280
Mean 18.75 144.7273 44.54167 57.61429 75.92718 263.3333 710.359 280
3rd Qu. 27.75 121.0000 50.25000 70.75000 89.50000 344.5000 1268.000 395
Max. 33.00 2200.0000 582.00000 352.00000 648.00000 520.0000 2200.000 500

Trial Group Type

group_type Group_Count
Experimental 604
Active Comparator 63
NA 44
Other 16
No Intervention 13
Placebo Comparator 10
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 335
Parallel Assignment 114
NA 13
Sequential Assignment 6
Factorial Assignment 4
Crossover Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 429
Supportive Care 19
Diagnostic 12
Prevention 7
Basic Science 2
Other 2
Screening 2
NA 2

Observational Studies

Studies by Country

Country Study_Count
United States 32
Italy 6
NA 5
France 4
Japan 3
United Kingdom 3
Brazil 2
Canada 2
Israel 2
Austria|Italy|Netherlands|Spain 1
Korea, Republic of 1
Mexico 1
Netherlands 1
Russian Federation 1
United States|Australia|Canada|Switzerland 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 52
2 4
3 2
4 1
5 1
8 1
11 1
15 1
40 1
66 1
183 1

Enrollment Metrics

Measure Observational
Min 5.0000
1st Qu 40.0000
Median 121.0000
Mean 487.1077
3rd Qu 335.0000
Max 9999.0000

Observation Model

observational_model Study_Count
Cohort 37
Case-Only 15
Case-Control 4
NA 4
Family-Based 2
Other 2
Case-Crossover 1
Case Control 1

Time Perspective

time_perspective Study_Count
Prospective 37
Retrospective 17
Other 6
Cross-Sectional 4
NA 2

Registries

Studies by Country

Country Study_Count
Korea, Republic of 2
United States 2
Russian Federation 1

Sites per Study

Site_count Study_Count
1 4
9 1

Enrollment Metrics

Measure Registries
Min 48.0
1st Qu 70.0
Median 150.0
Mean 573.6
3rd Qu 600.0
Max 2000.0

Registry Model

observational_model Study_Count
Cohort 3
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 4
Other 1

Follow-up

target_duration Study_Count
1 Year 2
3 Years 2
15 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04459416 Managing Pain Caused by Chemotherapy in People With Myeloma or Lymphoma https://ClinicalTrials.gov/show/NCT04459416 Recruiting Memorial Sloan Kettering Cancer Center 2023-06-30
NCT04318080 Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04318080 Recruiting BeiGene 2022-10-31
NCT03947255 A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03947255 Recruiting Seattle Genetics, Inc. 2024-12-31
NCT03907488 Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03907488 Recruiting National Cancer Institute (NCI) 2024-03-01
NCT03755414 Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation https://ClinicalTrials.gov/show/NCT03755414 Recruiting Washington University School of Medicine 2022-06-30
NCT03646123 Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03646123 Recruiting Seattle Genetics, Inc. 2022-07-07
NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) https://ClinicalTrials.gov/show/NCT03407144 Recruiting Merck Sharp & Dohme Corp. 2027-02-13
NCT03343665 Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT03343665 Completed St. Petersburg State Pavlov Medical University 2019-12-20
NCT03343652 A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03343652 Completed St. Petersburg State Pavlov Medical University 2019-03-27
NCT03337919 ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03337919 Recruiting University College, London 2022-05-31
NCT03331341 Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03331341 Recruiting University of Washington 2021-12-01
NCT03250962 SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03250962 Recruiting Chinese PLA General Hospital 2022-07-21
NCT03236935 Phase Ib of L-NMMA and Pembrolizumab https://ClinicalTrials.gov/show/NCT03236935 Recruiting The Methodist Hospital System 2020-01-01
NCT03233347 Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03233347 Recruiting Academic and Community Cancer Research United 2023-08-01
NCT03226249 PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03226249 Active, not recruiting Northwestern University 2020-08-01
NCT03209973 A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03209973 Active, not recruiting BeiGene 2018-07-23
NCT03179917 Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03179917 Recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT03159897 FIL Study on ABVD DD-DI as Upfront Therapy in HL. https://ClinicalTrials.gov/show/NCT03159897 Recruiting Fondazione Italiana Linfomi ONLUS 2023-01-31
NCT03154710 Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response https://ClinicalTrials.gov/show/NCT03154710 Recruiting Weprom 2022-01-31
NCT03150329 Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03150329 Recruiting City of Hope Medical Center 2020-07-18
NCT03138499 A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, https://ClinicalTrials.gov/show/NCT03138499 Active, not recruiting Bristol-Myers Squibb 2020-11-29
NCT03125642 Auto Stem Cell Transplant for Lymphoma Patients https://ClinicalTrials.gov/show/NCT03125642 Recruiting Masonic Cancer Center, University of Minnesota 2023-04-30
NCT03114683 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03114683 Completed Innovent Biologics (Suzhou) Co. Ltd. 2018-12-30
NCT03107663 ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03107663 Completed ImaginAb, Inc. 2018-08-16
NCT03077828 Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03077828 Recruiting Northwestern University 2022-11-30
NCT03057795 Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03057795 Recruiting City of Hope Medical Center 2020-10-08
NCT03049449 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas https://ClinicalTrials.gov/show/NCT03049449 Recruiting National Institutes of Health Clinical Center (CC) 2021-06-30
NCT03044743 PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies https://ClinicalTrials.gov/show/NCT03044743 Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 2020-03-31
NCT03038672 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas https://ClinicalTrials.gov/show/NCT03038672 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT03033914 A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) https://ClinicalTrials.gov/show/NCT03033914 Recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT03016871 Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL https://ClinicalTrials.gov/show/NCT03016871 Recruiting City of Hope Medical Center 2021-06-22
NCT03013933 Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03013933 Recruiting City of Hope Medical Center 2020-08-26
NCT03004833 Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03004833 Active, not recruiting University of Cologne 2020-12-31
NCT02996773 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine https://ClinicalTrials.gov/show/NCT02996773 Recruiting University of Arizona 2022-11-29
NCT02981914 Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02981914 Recruiting University of Chicago 2023-02-28
NCT02979522 A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02979522 Active, not recruiting Takeda 2020-06-30
NCT02973113 Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) https://ClinicalTrials.gov/show/NCT02973113 Active, not recruiting Baylor College of Medicine 2021-04-16
NCT02940301 Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02940301 Recruiting Ohio State University Comprehensive Cancer Center 2020-05-31
NCT02939014 Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) https://ClinicalTrials.gov/show/NCT02939014 Completed Takeda 2018-08-02
NCT02875067 Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02875067 Completed NYU Langone Health 2017-10-02
NCT02869633 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02869633 Active, not recruiting Vanderbilt-Ingram Cancer Center 2021-10-31
NCT02824029 Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02824029 Recruiting Barbara Ann Karmanos Cancer Institute 2019-04-30
NCT02815137 Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02815137 Recruiting Centre Henri Becquerel 2018-12-31
NCT02797717 Treatment for Classical Hodgkin Lymphoma in Children and Adolescents https://ClinicalTrials.gov/show/NCT02797717 Recruiting Rabin Medical Center 2022-12-31
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02758717 Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02758717 Active, not recruiting Academic and Community Cancer Research United 2019-08-13
NCT02686346 Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE https://ClinicalTrials.gov/show/NCT02686346 Active, not recruiting The Lymphoma Academic Research Organisation 2018-10-31
NCT02684708 Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents https://ClinicalTrials.gov/show/NCT02684708 Recruiting University of Giessen 2026-09-30
NCT02684292 Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) https://ClinicalTrials.gov/show/NCT02684292 Active, not recruiting Merck Sharp & Dohme Corp. 2023-12-30
NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03213665 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02665650 Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02665650 Completed Affimed GmbH 2019-01-31
NCT02663297 Administration of T Lymphocytes for Prevention of Relapse of Lymphomas https://ClinicalTrials.gov/show/NCT02663297 Recruiting UNC Lineberger Comprehensive Cancer Center 2021-09-30
NCT02661503 HD21 for Advanced Stages https://ClinicalTrials.gov/show/NCT02661503 Recruiting University of Cologne 2020-06-30
NCT02639559 Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT02639559 Active, not recruiting Washington University School of Medicine 2018-04-12
NCT02626884 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) https://ClinicalTrials.gov/show/NCT02626884 Active, not recruiting University of Cologne 2020-12-31
NCT01896999 Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01896999 Recruiting National Cancer Institute (NCI) 2025-03-20
NCT01087294 Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01087294 Recruiting National Institutes of Health Clinical Center (CC) 2023-03-01
NCT02576496 Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02576496 Recruiting Mundipharma-EDO GmbH 2021-03-31
NCT02595866 Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms https://ClinicalTrials.gov/show/NCT02595866 Recruiting National Cancer Institute (NCI) 2021-07-01
NCT02572167 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02572167 Active, not recruiting Seattle Genetics, Inc. 2018-03-01
NCT02376699 Safety Study of SEA-CD40 in Cancer Patients https://ClinicalTrials.gov/show/NCT02376699 Recruiting Seattle Genetics, Inc. 2021-10-31
NCT01716806 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01716806 Recruiting Seattle Genetics, Inc. 2021-09-30
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02568553 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02567851 A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity https://ClinicalTrials.gov/show/NCT02567851 Completed University of Birmingham 2016-01-14
NCT01100502 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) https://ClinicalTrials.gov/show/NCT01100502 Completed Seattle Genetics, Inc. 2014-08-31
NCT02526823 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma https://ClinicalTrials.gov/show/NCT02526823 Recruiting Shandong Provincial Hospital 2019-12-31
NCT02505269 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02505269 Active, not recruiting Massachusetts General Hospital 2019-06-30
NCT02467946 Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient https://ClinicalTrials.gov/show/NCT02467946 Active, not recruiting Centre Antoine Lacassagne 2019-12-31
NCT02453594 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) https://ClinicalTrials.gov/show/NCT02453594 Active, not recruiting Merck Sharp & Dohme Corp. 2021-04-20
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02429375 Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02429375 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT02414568 Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin https://ClinicalTrials.gov/show/NCT02414568 Active, not recruiting The Lymphoma Academic Research Organisation 2018-12-14
NCT02398240 Brentuximab for Newly Diagnosed Hodgkin Disease https://ClinicalTrials.gov/show/NCT02398240 Recruiting New York Medical College 2020-12-31
NCT02396134 Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02396134 Recruiting City of Hope Medical Center 2020-05-31
NCT02389101 Molecular and Whole-body MR Imaging in Lymphomas https://ClinicalTrials.gov/show/NCT02389101 Completed Turku University Hospital 2016-03-31
NCT02362997 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL https://ClinicalTrials.gov/show/NCT02362997 Recruiting Dana-Farber Cancer Institute 2020-09-30
NCT02321592 GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02321592 Active, not recruiting University of Cologne 2020-12-31
NCT02304458 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas https://ClinicalTrials.gov/show/NCT02304458 Active, not recruiting National Cancer Institute (NCI) 2021-01-31
NCT02298283 Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD https://ClinicalTrials.gov/show/NCT02298283 Active, not recruiting The Lymphoma Academic Research Organisation 2020-08-31
NCT02298257 A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02298257 Active, not recruiting The Lymphoma Academic Research Organisation 2020-06-30
NCT02292979 Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. https://ClinicalTrials.gov/show/NCT02292979 Active, not recruiting The Lymphoma Academic Research Organisation 2016-12-31
NCT02287311 Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) https://ClinicalTrials.gov/show/NCT02287311 Recruiting Baylor College of Medicine 2021-02-28
NCT02247869 Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02247869 Completed Fondazione Italiana Linfomi ONLUS 2015-06-30
NCT02244021 BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV https://ClinicalTrials.gov/show/NCT02244021 Completed Fondazione Italiana Linfomi ONLUS 2016-07-31
NCT02243436 Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02243436 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2019-01-31
NCT02240719 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer https://ClinicalTrials.gov/show/NCT02240719 Completed University of California, Davis 2018-04-09
NCT02227433 Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. https://ClinicalTrials.gov/show/NCT02227433 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2018-04-03
NCT02227199 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02227199 Active, not recruiting University of Washington 2020-03-30
NCT02213913 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02213913 Recruiting University of Chicago 2020-07-29
NCT02191930 Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02191930 Recruiting University of Cologne 2018-12-31
NCT02181738 Study of Nivolumab in Patients With Classical Hodgkin’s Lymphoma (Registrational) https://ClinicalTrials.gov/show/NCT02181738 Active, not recruiting Bristol-Myers Squibb 2017-08-31
NCT02181478 Intra-Osseous Co-Transplant of UCB and hMSC https://ClinicalTrials.gov/show/NCT02181478 Active, not recruiting Case Comprehensive Cancer Center 2019-12-19
NCT02181218 Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT02181218 Active, not recruiting Washington University School of Medicine 2019-03-28
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT02166463 Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02166463 Active, not recruiting National Cancer Institute (NCI) 2020-12-31
NCT02164500 JAK-inhibition in Recurrent Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02164500 Completed University of Cologne 2019-05-17
NCT02164006 Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT02164006 Completed TG Therapeutics, Inc. 2016-05-31
NCT02104427 PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients https://ClinicalTrials.gov/show/NCT02104427 Completed TaiGen Biotechnology Co., Ltd. 2015-11-30
NCT02098512 Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients https://ClinicalTrials.gov/show/NCT02098512 Recruiting New York Medical College 2019-12-31
NCT02059239 Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma https://ClinicalTrials.gov/show/NCT02059239 Active, not recruiting Weill Medical College of Cornell University 2019-12-16
NCT01316146 Administration of T Lymphocytes for Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma (CART CD30) https://ClinicalTrials.gov/show/NCT01316146 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2016-01-28
NCT01315132 A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01315132 Completed Thomas Jefferson University 2018-09-19
NCT01304849 Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin’s Lymphoma in Order to Improve Outcomes https://ClinicalTrials.gov/show/NCT01304849 Completed Cancer Institute WIA 2013-09-30
NCT01283776 Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01283776 Completed University of Cologne 2013-12-31
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT03096782 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT03096782 Recruiting M.D. Anderson Cancer Center 2020-10-31
NCT01271127 Screening for Coronary Artery Disease After Mediastinal Irradiation https://ClinicalTrials.gov/show/NCT01271127 Completed Leiden University Medical Center 2013-06-30
NCT03800706 A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03800706 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-02-28
NCT02003625 Meloxicam vs Placebo for Mobilization https://ClinicalTrials.gov/show/NCT02003625 Completed Massachusetts General Hospital 2019-02-28
NCT01998035 Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01998035 Active, not recruiting Columbia University 2019-12-31
NCT01990534 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01990534 Completed Takeda 2016-03-24
NCT01969435 Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma https://ClinicalTrials.gov/show/NCT01969435 Completed Washington University School of Medicine 2015-09-30
NCT01965119 Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT01965119 Completed Samsung Medical Center 2017-06-30
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01956084 Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma https://ClinicalTrials.gov/show/NCT01956084 Active, not recruiting Children’s National Research Institute 2020-09-30
NCT01951885 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention https://ClinicalTrials.gov/show/NCT01951885 Recruiting Case Comprehensive Cancer Center 2020-07-31
NCT01950364 A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01950364 Completed Millennium Pharmaceuticals, Inc. 2014-10-31
NCT01947140 Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01947140 Recruiting Columbia University 2021-01-31
NCT01921387 Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01921387 Active, not recruiting Fred Hutchinson Cancer Research Center 2017-07-26
NCT01920932 Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01920932 Active, not recruiting St. Jude Children’s Research Hospital 2020-11-16
NCT01902160 Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01902160 Completed National Cancer Institute (NCI) 2015-05-31
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01877005 A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01877005 Completed The Lymphoma Academic Research Organisation 2015-06-30
NCT01874054 Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01874054 Completed Seattle Genetics, Inc. 2015-12-31
NCT01868451 Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01868451 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-05-31
NCT01858922 Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A https://ClinicalTrials.gov/show/NCT01858922 Active, not recruiting Baylor College of Medicine 2020-06-30
NCT01854567 P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01854567 Completed Mesoblast, Ltd. 2016-09-23
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01833884 Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic https://ClinicalTrials.gov/show/NCT01833884 Completed Centre Henri Becquerel 2016-05-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01771107 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01771107 Active, not recruiting National Cancer Institute (NCI) 2021-10-16
NCT01768845 Unrelated Umbilical Cord Blood (UBC)Transplantation https://ClinicalTrials.gov/show/NCT01768845 Active, not recruiting West Virginia University 2019-05-14
NCT01764230 Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients https://ClinicalTrials.gov/show/NCT01764230 Completed Masaryk University 2007-07-31
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01712490 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01712490 Active, not recruiting Takeda 2017-04-20
NCT01703949 Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma https://ClinicalTrials.gov/show/NCT01703949 Recruiting University of Washington 2021-01-15
NCT01702961 Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT01702961 Completed Baylor College of Medicine 2014-08-31
NCT01696461 A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor https://ClinicalTrials.gov/show/NCT01696461 Completed Center for International Blood and Marrow Transplant Research 2016-08-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01665768 Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma https://ClinicalTrials.gov/show/NCT01665768 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2017-10-31
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01657331 Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) https://ClinicalTrials.gov/show/NCT01657331 Active, not recruiting Columbia University 2019-12-31
NCT01619761 NK Cells in Cord Blood Transplantation https://ClinicalTrials.gov/show/NCT01619761 Active, not recruiting M.D. Anderson Cancer Center 2021-11-30
NCT01611298 Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR https://ClinicalTrials.gov/show/NCT01611298 Completed Baylor College of Medicine 2012-11-30
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01578967 Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01578967 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2016-08-10
NCT01572662 Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning https://ClinicalTrials.gov/show/NCT01572662 Active, not recruiting M.D. Anderson Cancer Center 2020-04-30
NCT01572519 A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01572519 Completed Janssen Research & Development, LLC 2013-08-13
NCT01569204 Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01569204 Completed University of Cologne 2014-03-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01555892 Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE https://ClinicalTrials.gov/show/NCT01555892 Recruiting Baylor College of Medicine 2020-12-31
NCT01535924 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01535924 Completed Ohio State University Comprehensive Cancer Center 2019-02-20
NCT01534078 Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01534078 Completed Massachusetts General Hospital 2015-01-31
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523847 A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin’s Lymphoma (HL) https://ClinicalTrials.gov/show/NCT01523847 Completed Fondazione Italiana Linfomi ONLUS 2013-10-31
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01508312 Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01508312 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT01499147 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01499147 Completed University of Illinois at Chicago 2013-05-31
NCT01492088 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01492088 Completed Takeda 2016-10-12
NCT01487031 Music Therapy on Nausea and Pain for Autologous Stem Cell https://ClinicalTrials.gov/show/NCT01487031 Completed Case Comprehensive Cancer Center 2013-04-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01476410 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01476410 Active, not recruiting Northwestern University 2021-05-31
NCT01468311 Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01468311 Active, not recruiting National Institutes of Health Clinical Center (CC) 2014-11-16
NCT01460940 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01460940 Completed Ohio State University Comprehensive Cancer Center 2016-11-16
NCT01458288 A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease https://ClinicalTrials.gov/show/NCT01458288 Completed TaiGen Biotechnology Co., Ltd. 2013-07-31
NCT01453504 Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01453504 Completed University of Cologne 2019-03-31
NCT01447056 Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases https://ClinicalTrials.gov/show/NCT01447056 Completed Baylor College of Medicine 2015-03-31
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01404936 Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT01404936 Completed M.D. Anderson Cancer Center 2011-12-31
NCT01393717 Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01393717 Completed City of Hope Medical Center 2017-02-01
NCT01393106 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01393106 Completed Gilead Sciences 2014-08-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01358747 Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL https://ClinicalTrials.gov/show/NCT01358747 Completed Centre Hospitalier Universitaire Dijon NA
NCT01356680 HD17 for Intermediate Stage Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01356680 Completed University of Cologne 2020-03-21
NCT01350245 Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor https://ClinicalTrials.gov/show/NCT01350245 Completed Thomas Jefferson University 2013-05-31
NCT01336712 Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases https://ClinicalTrials.gov/show/NCT01336712 Completed Northside Hospital, Inc. 2014-12-31
NCT01333046 Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL https://ClinicalTrials.gov/show/NCT01333046 Recruiting Baylor College of Medicine 2021-01-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT01321346 A Study Of Panobinostat In Children With Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01321346 Completed Therapeutic Advances in Childhood Leukemia Consortium 2015-10-31
NCT04292626 Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose https://ClinicalTrials.gov/show/NCT04292626 Enrolling by invitation Tomsk National Research Medical Center of the Russian Academy of Sciences 2021-02-19
NCT04270266 Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04270266 Recruiting M.D. Anderson Cancer Center 2021-06-30
NCT04239170 Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04239170 Recruiting Peking University 2022-12-31
NCT04233294 Chidamide in Combination With Camrelizumab Alone or Plus Decitabine in Relapsed/Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04233294 Recruiting Chinese PLA General Hospital 2024-02-29
NCT04134325 Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04134325 Recruiting UNC Lineberger Comprehensive Cancer Center 2021-12-01
NCT04090268 Precision Exercise in Children With Malignant Hemopathies https://ClinicalTrials.gov/show/NCT04090268 Recruiting University of Milano Bicocca 2021-04-03
NCT04067037 Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT04067037 Recruiting Henan Cancer Hospital 2022-06-30
NCT04052997 Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04052997 Active, not recruiting ADC Therapeutics S.A. 2021-11-30
NCT04044222 A Study to Evaluate the Efficacy and Safety of the Sintilimab Plus ICE Regimen Versus ICE Regimen in the Classic Hodgkin’s Lymphoma Patients (cHL) Who Have Failed the First-line Standard Chemotherapy https://ClinicalTrials.gov/show/NCT04044222 Recruiting Innovent Biologics (Suzhou) Co. Ltd. 2023-07-30
NCT04026269 Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen https://ClinicalTrials.gov/show/NCT04026269 Recruiting Chinese PLA General Hospital 2020-12-31
NCT03968250 CBT on Fatigue in Survivors of Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03968250 Active, not recruiting University of Leipzig 2020-08-20
NCT03935282 Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors https://ClinicalTrials.gov/show/NCT03935282 Enrolling by invitation Wake Forest University Health Sciences 2023-05-31
NCT03921879 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT03921879 Recruiting Oncotartis, Inc. 2021-04-30
NCT03776864 Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03776864 Recruiting University of Washington 2022-11-01
NCT03755804 Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 https://ClinicalTrials.gov/show/NCT03755804 Recruiting St. Jude Children’s Research Hospital 2027-01-01
NCT03739619 Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03739619 Recruiting Emory University 2022-11-30
NCT03739502 A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03739502 Recruiting University of Rochester 2021-04-30
NCT03722147 A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03722147 Recruiting Akeso 2020-03-01
NCT03712202 Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03712202 Recruiting City of Hope Medical Center 2020-08-23
NCT03681561 Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03681561 Recruiting Big Ten Cancer Research Consortium 2020-09-30
NCT03655483 Study of GLS-010 Injection in the Treatment of Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03655483 Active, not recruiting Guangzhou Gloria Biosciences Co., Ltd. 2021-04-11
NCT03617666 Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study https://ClinicalTrials.gov/show/NCT03617666 Recruiting University College, London 2020-10-31
NCT03615664 The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy https://ClinicalTrials.gov/show/NCT03615664 Recruiting Polish Lymphoma Research Group 2021-05-06
NCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) https://ClinicalTrials.gov/show/NCT03598608 Recruiting Merck Sharp & Dohme Corp. 2025-11-05
NCT03580408 Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03580408 Recruiting The Lymphoma Academic Research Organisation 2020-12-31
NCT03540849 BV After Allogeneic Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03540849 Recruiting University Hospital, Caen 2020-03-07
NCT03527628 OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy https://ClinicalTrials.gov/show/NCT03527628 Recruiting King Abdullah International Medical Research Center 2021-01-15
NCT03524235 Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL https://ClinicalTrials.gov/show/NCT03524235 Recruiting Cedars-Sinai Medical Center 2021-05-31
NCT03517137 Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study https://ClinicalTrials.gov/show/NCT03517137 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-03-01
NCT03500133 Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation. https://ClinicalTrials.gov/show/NCT03500133 Recruiting Hospital JP Garrahan 2027-10-31
NCT03480334 Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy https://ClinicalTrials.gov/show/NCT03480334 Recruiting University of Cologne 2021-05-31
NCT03436862 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk https://ClinicalTrials.gov/show/NCT03436862 Recruiting SCRI Development Innovations, LLC 2021-09-30
NCT01263899 A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01263899 Completed S*BIO 2012-02-29
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01251107 Study Comparing ABVD vs BEACOPP in Advanced Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01251107 Completed Fondazione Michelangelo 2009-11-30
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01221571 A Study to Assess AFM13 in Patients With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01221571 Completed Affimed GmbH 2013-05-31
NCT01207921 Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT01207921 Active, not recruiting Washington University School of Medicine 2016-09-19
NCT01200329 High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT01200329 Completed M.D. Anderson Cancer Center 2018-12-06
NCT01195766 Study of Ofatumumab and ESHAP for the Treatment of Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01195766 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2013-09-30
NCT01192464 EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma https://ClinicalTrials.gov/show/NCT01192464 Active, not recruiting Baylor College of Medicine 2012-05-29
NCT01188798 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01188798 Completed St. Jude Children’s Research Hospital 2012-02-29
NCT01187303 Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) https://ClinicalTrials.gov/show/NCT01187303 Completed University of Cologne 2013-11-30
NCT01181271 Tandem Auto-Allo Transplant for Lymphoma https://ClinicalTrials.gov/show/NCT01181271 Completed Massachusetts General Hospital 2014-02-28
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01221857 Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01221857 Completed Gamida Cell ltd 2012-09-30
NCT01169636 Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01169636 Completed M.D. Anderson Cancer Center 2017-05-17
NCT01165112 Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01165112 Completed University of Washington 2015-06-30
NCT01164345 Mozobil for Autologous Stem Cell Mobilization https://ClinicalTrials.gov/show/NCT01164345 Completed Sheba Medical Center 2015-05-31
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01158118 Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors https://ClinicalTrials.gov/show/NCT01158118 Completed Washington University School of Medicine 2014-01-15
NCT01149668 A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer https://ClinicalTrials.gov/show/NCT01149668 Completed Pharmacyclics LLC. 2012-12-31
NCT01132807 Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01132807 Completed Alliance for Clinical Trials in Oncology 2016-02-29
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01121120 Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients https://ClinicalTrials.gov/show/NCT01121120 Active, not recruiting Tarix Pharmaceuticals 2020-06-30
NCT01118026 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01118026 Active, not recruiting Alliance for Clinical Trials in Oncology 2020-08-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01088750 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01088750 Active, not recruiting Martin-Luther-Universität Halle-Wittenberg 2023-10-31
NCT01085058 Predictive Value of the “Cytocapacity Test” Patients With Lymphoproliferative Diseases and High-dose Therapy https://ClinicalTrials.gov/show/NCT01085058 Completed WiSP Wissenschaftlicher Service Pharma GmbH 2004-12-31
NCT01076543 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01076543 Completed National Cancer Institute (NCI) 2017-12-31
NCT01060904 A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01060904 Completed Seattle Genetics, Inc. 2012-09-30
NCT01056679 Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients https://ClinicalTrials.gov/show/NCT01056679 Completed University of Cologne 2014-04-30
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01045382 MSC and HSC Coinfusion in Mismatched Minitransplants https://ClinicalTrials.gov/show/NCT01045382 Recruiting University of Liege 2021-07-31
NCT01037478 Resminostat (4SC-201) in Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01037478 Completed 4SC AG 2012-01-31
NCT01034163 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin’s Lymphoma (HL) https://ClinicalTrials.gov/show/NCT01034163 Completed Novartis 2012-05-31
NCT01030900 Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT01030900 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-09-01
NCT01026415 Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) https://ClinicalTrials.gov/show/NCT01026415 Completed Seattle Genetics, Inc. 2012-05-31
NCT01026233 Cardiac Safety Study of Brentuximab Vedotin (SGN-35) https://ClinicalTrials.gov/show/NCT01026233 Completed Seattle Genetics, Inc. 2010-08-31
NCT01022996 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. https://ClinicalTrials.gov/show/NCT01022996 Completed Novartis 2014-11-30
NCT01018979 Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients https://ClinicalTrials.gov/show/NCT01018979 Completed TaiGen Biotechnology Co., Ltd. 2011-10-31
NCT01014507 Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01014507 Completed University of Cologne 2009-09-30
NCT01008462 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01008462 Completed Fred Hutchinson Cancer Research Center 2018-06-30
NCT01004718 Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT) https://ClinicalTrials.gov/show/NCT01004718 Completed Abramson Cancer Center of the University of Pennsylvania 2013-07-31
NCT00992030 R-ABVD vs ABVD-RT in Early Stage Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00992030 Active, not recruiting Fondazione Michelangelo 2019-11-30
NCT00990717 Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies https://ClinicalTrials.gov/show/NCT00990717 Completed University Health Network, Toronto 2012-07-31
NCT00990587 Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy https://ClinicalTrials.gov/show/NCT00990587 Completed University Health Network, Toronto 2013-05-31
NCT00982449 124I-FIAU Imaging in EBV and KSHV Associated Cancers https://ClinicalTrials.gov/show/NCT00982449 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2013-07-31
NCT00975975 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer https://ClinicalTrials.gov/show/NCT00975975 Completed Indiana University 2012-10-31
NCT00967369 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. https://ClinicalTrials.gov/show/NCT00967369 Completed M.D. Anderson Cancer Center 2018-05-02
NCT00952237 Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF https://ClinicalTrials.gov/show/NCT00952237 Completed Dartmouth-Hitchcock Medical Center 2011-04-30
NCT00947856 A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study https://ClinicalTrials.gov/show/NCT00947856 Completed Seattle Genetics, Inc. 2013-03-31
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00901225 Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00901225 Completed Duke University 2010-08-31
NCT00901069 Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00901069 Completed University of Kentucky 2012-01-31
NCT00891592 Umbilical Cord Blood Transplant for Hematological Malignancies https://ClinicalTrials.gov/show/NCT00891592 Completed University of Pennsylvania 2011-11-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00887718 Positron Emission Tomography(PET) in Lymphoma Assessment https://ClinicalTrials.gov/show/NCT00887718 Completed University Health Network, Toronto 2011-06-30
NCT00871702 Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease https://ClinicalTrials.gov/show/NCT00871702 Completed Washington University School of Medicine 2012-11-30
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00850200 Proton Therapy for Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00850200 Completed University of Florida 2013-05-31
NCT00848926 A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00848926 Completed Seattle Genetics, Inc. 2010-08-31
NCT00846742 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00846742 Active, not recruiting St. Jude Children’s Research Hospital 2019-01-11
NCT02867618 Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma https://ClinicalTrials.gov/show/NCT02867618 Recruiting Columbia University 2020-10-31
NCT00822120 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00822120 Active, not recruiting Southwest Oncology Group 2016-04-30
NCT02593123 Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis https://ClinicalTrials.gov/show/NCT02593123 Active, not recruiting Virginia Commonwealth University 2025-12-31
NCT01527838 Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit https://ClinicalTrials.gov/show/NCT01527838 Completed Fate Therapeutics 2013-10-31
NCT00838357 A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). https://ClinicalTrials.gov/show/NCT00838357 Completed Sanofi 2010-11-30
NCT01758042 Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders https://ClinicalTrials.gov/show/NCT01758042 Recruiting Massachusetts General Hospital 2019-07-31
NCT01413568 Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01413568 Completed Polyphor Ltd. 2015-11-30
NCT03878524 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial https://ClinicalTrials.gov/show/NCT03878524 Recruiting OHSU Knight Cancer Institute 2022-02-27
NCT00802113 Autologous and Allogeneic Transplant for Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT00802113 Completed Columbia University 2014-10-31
NCT01217229 Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01217229 Completed Daiichi Sankyo, Inc. 2012-04-26
NCT03618550 Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03618550 Recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT02927769 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin’s Lymphoma (cHL), Relapsed or Refractory From First Line Treatment https://ClinicalTrials.gov/show/NCT02927769 Recruiting Bristol-Myers Squibb 2023-03-27
NCT03576378 BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) https://ClinicalTrials.gov/show/NCT03576378 Recruiting Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2023-10-30
NCT01780662 Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01780662 Active, not recruiting National Cancer Institute (NCI) 2017-09-30
NCT01701986 Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01701986 Recruiting M.D. Anderson Cancer Center 2020-05-01
NCT01476839 Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01476839 Active, not recruiting City of Hope Medical Center 2021-01-31
NCT03697408 Itacitinib + Everolimus in Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03697408 Recruiting University of Pennsylvania 2026-01-31
NCT03505996 A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03505996 Recruiting CStone Pharmaceuticals 2019-12-31
NCT03474133 Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin’s Lymphoma (BASALT) https://ClinicalTrials.gov/show/NCT03474133 Recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology 2023-10-01
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT00792467 Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients https://ClinicalTrials.gov/show/NCT00792467 Completed Italfarmaco 2010-07-31
NCT00784537 High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients https://ClinicalTrials.gov/show/NCT00784537 Completed Fondazione Italiana Linfomi ONLUS 2015-01-31
NCT00779584 A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) https://ClinicalTrials.gov/show/NCT00779584 Completed Merck Sharp & Dohme Corp. 2011-05-28
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00754286 A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer https://ClinicalTrials.gov/show/NCT00754286 Completed Albert Einstein College of Medicine 2011-07-31
NCT00742027 Phase II Study of Oral Panobinostat in Adult Patients With Relapsed/Refractory Classical Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00742027 Completed Novartis 2013-08-31
NCT00741871 A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00741871 Completed S*BIO 2011-10-31
NCT00736320 HD16 for Early Stage Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00736320 Active, not recruiting University of Cologne 2018-09-30
NCT00733824 Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00733824 Completed Washington University School of Medicine 2012-09-30
NCT00724984 Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00724984 Completed Pharmacyclics LLC. 2012-11-30
NCT00718757 Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00718757 Completed St. Jude Children’s Research Hospital 2009-01-31
NCT00705250 Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00705250 Completed Memorial Sloan Kettering Cancer Center 2015-12-31
NCT00697684 Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00697684 Active, not recruiting Dana-Farber Cancer Institute 2020-12-31
NCT00691210 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00691210 Completed Columbia University 2014-02-28
NCT00683046 T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00683046 Completed University of Chicago 2014-12-31
NCT00678327 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00678327 Active, not recruiting University College, London 2016-01-31
NCT00670592 Study of HCD122 in Adults With Non-Hodgkin’s or Hodgkin’s Lymphoma Who Have Progressed After at Least Two Prior Therapies https://ClinicalTrials.gov/show/NCT00670592 Completed Novartis 2013-02-28
NCT00667615 Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT00667615 Completed Memorial Sloan Kettering Cancer Center 2017-02-28
NCT00666484 Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00666484 Completed University College, London 2012-09-30
NCT00665314 Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). https://ClinicalTrials.gov/show/NCT00665314 Completed Sanofi 2008-04-30
NCT00654732 Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00654732 Completed M.D. Anderson Cancer Center 2018-09-05
NCT00652626 Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function https://ClinicalTrials.gov/show/NCT00652626 Completed Celgene 2012-07-01
NCT00648037 Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT https://ClinicalTrials.gov/show/NCT00648037 Completed Memorial Sloan Kettering Cancer Center 2008-12-31
NCT00636909 Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders https://ClinicalTrials.gov/show/NCT00636909 Completed Beth Israel Deaconess Medical Center 2006-03-31
NCT00636311 A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00636311 Completed Istituto Clinico Humanitas 2008-04-30
NCT00634452 Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00634452 Completed Bristol-Myers Squibb 2010-01-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00606645 Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00606645 Completed Xencor, Inc. 2010-04-30
NCT00606437 Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants https://ClinicalTrials.gov/show/NCT00606437 Completed Duke University 2014-02-28
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00601146 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00601146 Completed Dana-Farber Cancer Institute 2010-12-01
NCT00597714 Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00597714 Completed Duke University 2013-07-31
NCT00592111 A Comprehensive Study of Clinically Staged Pediatric Hodgkin’s Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) https://ClinicalTrials.gov/show/NCT00592111 Completed Memorial Sloan Kettering Cancer Center 1999-02-28
NCT00587873 Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin’s Disease (Phase II) https://ClinicalTrials.gov/show/NCT00587873 Completed Memorial Sloan Kettering Cancer Center 2003-12-31
NCT00581815 Spectroscopy With Surface Coils and Decoupling https://ClinicalTrials.gov/show/NCT00581815 Completed Memorial Sloan Kettering Cancer Center 2014-02-28
NCT00577798 Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin https://ClinicalTrials.gov/show/NCT00577798 Completed University of Nebraska 2012-12-31
NCT00574496 Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00574496 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT00571662 Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00571662 Completed University of Nebraska 2008-12-31
NCT00562224 Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients https://ClinicalTrials.gov/show/NCT00562224 Completed Pharmacyclics LLC. 2010-06-30
NCT00551798 Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin’s Disease and Lymphoma Malins High Grade https://ClinicalTrials.gov/show/NCT00551798 Completed University Hospital, Limoges 2011-01-31
NCT00540007 Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00540007 Completed Washington University School of Medicine 2016-09-01
NCT00539695 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD https://ClinicalTrials.gov/show/NCT00539695 Completed Baylor College of Medicine 2013-04-30
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00534989 Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT https://ClinicalTrials.gov/show/NCT00534989 Completed King Faisal Specialist Hospital & Research Center 2013-02-28
NCT00534820 Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00534820 Completed King Faisal Specialist Hospital & Research Center 2013-08-31
NCT00533923 Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders https://ClinicalTrials.gov/show/NCT00533923 Completed Beth Israel Deaconess Medical Center 2007-01-31
NCT00516217 Galiximab in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00516217 Completed Alliance for Clinical Trials in Oncology 2011-09-30
NCT00515554 HD18 for Advanced Stages in Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT00515554 Active, not recruiting University of Cologne 2020-06-30
NCT00504504 Rituximab and ABVD for Hodgkin’s Patients https://ClinicalTrials.gov/show/NCT00504504 Completed M.D. Anderson Cancer Center 2012-03-31
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00484874 Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00484874 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2014-01-31
NCT00481871 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00481871 Completed Acrotech Biopharma LLC 2011-05-31
NCT00478959 Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00478959 Completed University Health Network, Toronto 2014-06-30
NCT00469729 Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy https://ClinicalTrials.gov/show/NCT00469729 Completed Gamida Cell -Teva Joint Venture Ltd. 2013-02-28
NCT00460694 Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies https://ClinicalTrials.gov/show/NCT00460694 Completed Singapore General Hospital 2012-12-31
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00444912 The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) https://ClinicalTrials.gov/show/NCT00444912 Completed Sanofi 2009-06-30
NCT00443677 Treatment of Advanced Hodgkin’s Disease (Stages IIB-III-IV) https://ClinicalTrials.gov/show/NCT00443677 Completed Gruppo Italiano Studio Linfomi NA
NCT00439361 Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00439361 Completed M.D. Anderson Cancer Center 2012-06-30
NCT00433459 Combination Chemotherapy in Treating Young Patients With Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00433459 Completed Martin-Luther-Universität Halle-Wittenberg 2013-01-31
NCT00433433 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00433433 Completed European Organisation for Research and Treatment of Cancer - EORTC 2011-12-31
NCT00430846 Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00430846 Completed Seattle Genetics, Inc. 2009-07-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT00423709 Allogeneic Blood Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00423709 Completed M.D. Anderson Cancer Center 2007-08-31
NCT00416832 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00416832 Completed Martin-Luther-Universität Halle-Wittenberg 2005-12-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00398554 Combination Chemotherapy in Treating Young Male Patients With Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00398554 Completed Martin-Luther-Universität Halle-Wittenberg 2012-10-31
NCT00398411 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells https://ClinicalTrials.gov/show/NCT00398411 Completed University of Cologne 2008-12-31
NCT00396201 AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00396201 Completed Sanofi 2006-10-31
NCT00392314 Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision. https://ClinicalTrials.gov/show/NCT00392314 Completed Rambam Health Care Campus 2014-05-31
NCT00388349 Gemcitabine and Hodgkin’s Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00388349 Completed Stanford University 2008-03-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00385788 Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00385788 Completed M.D. Anderson Cancer Center 2016-08-31
NCT00381940 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy https://ClinicalTrials.gov/show/NCT00381940 Completed National Cancer Institute (NCI) 2008-06-30
NCT00369681 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00369681 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2014-10-31
NCT00368082 Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) https://ClinicalTrials.gov/show/NCT00368082 Active, not recruiting Baylor College of Medicine 2013-09-30
NCT00364676 Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00364676 Completed Spectrum Pharmaceuticals, Inc 2015-06-30
NCT00359892 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00359892 Completed Teva Pharmaceutical Industries 2007-09-30
NCT00352027 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00352027 Active, not recruiting St. Jude Children’s Research Hospital 2015-05-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00346684 Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL) https://ClinicalTrials.gov/show/NCT00346684 Completed University of Cologne 2007-11-30
NCT00343564 A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00343564 Completed Cytokinetics 2010-07-31
NCT00337194 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00337194 Completed National Cancer Institute (NCI) 2008-09-30
NCT00305149 Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00305149 Completed Rambam Health Care Campus NA
NCT00302003 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00302003 Completed Children’s Oncology Group 2012-03-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00285259 Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) https://ClinicalTrials.gov/show/NCT00285259 Completed Astellas Pharma Inc 2009-11-30
NCT00284804 A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00284804 Completed Bristol-Myers Squibb 2008-05-31
NCT00284271 Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT00284271 Completed University of Cologne 2005-12-31
NCT00283439 A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma https://ClinicalTrials.gov/show/NCT00283439 Completed Amgen 2008-05-31
NCT00265031 HD12 for Advanced Stages https://ClinicalTrials.gov/show/NCT00265031 Completed University of Cologne NA
NCT00265018 HD10 for Early Stages https://ClinicalTrials.gov/show/NCT00265018 Completed University of Cologne 2003-01-31
NCT00264953 HD11 for Intermediate Stages https://ClinicalTrials.gov/show/NCT00264953 Completed University of Cologne 2003-01-31
NCT00262860 Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00262860 Completed University of Rochester 2008-05-31
NCT00261677 A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy https://ClinicalTrials.gov/show/NCT00261677 Completed Ortho Biotech Products, L.P. NA
NCT00256191 Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT00256191 Completed Cortice Biosciences, Inc. NA
NCT00255723 Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00255723 Completed Memorial Sloan Kettering Cancer Center 2012-07-31
NCT00241358 Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00241358 Completed Washington University School of Medicine 2009-12-31
NCT00232440 Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma https://ClinicalTrials.gov/show/NCT00232440 Completed University Health Network, Toronto 2009-06-30
NCT00196885 Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training https://ClinicalTrials.gov/show/NCT00196885 Completed German Cancer Research Center NA
NCT00186251 High Dose Chemotherapy Followed By PBSC Rescue for HD https://ClinicalTrials.gov/show/NCT00186251 Completed Stanford University NA
NCT00185692 Allogeneic Transplantation From Related Haploidentical Donors https://ClinicalTrials.gov/show/NCT00185692 Completed Stanford University 2010-12-31
NCT00165425 Cardiac Screening in Survivors of Hodgkin’s Disease Treated With Mediastinal Irradiation https://ClinicalTrials.gov/show/NCT00165425 Active, not recruiting Dana-Farber Cancer Institute 2007-10-31
NCT00165308 Tamoxifen in the Prevention of Breast Cancer in Hodgkin’s Disease Survivors https://ClinicalTrials.gov/show/NCT00165308 Completed Dana-Farber Cancer Institute 2004-03-31
NCT00145613 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies https://ClinicalTrials.gov/show/NCT00145613 Completed St. Jude Children’s Research Hospital 2006-07-31
NCT00163761 Efficacy Study of Outpatient Therapy for Lymphoma https://ClinicalTrials.gov/show/NCT00163761 Completed Bayside Health 2008-02-29
NCT00163748 Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma https://ClinicalTrials.gov/show/NCT00163748 Completed Bayside Health 2003-11-30
NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00150462 Completed Amgen 2009-10-31
NCT00147875 Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00147875 Completed University of Cologne 2007-07-31
NCT00145600 Therapy for Pediatric Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00145600 Active, not recruiting St. Jude Children’s Research Hospital 2012-05-31
NCT00144703 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00144703 Completed Dana-Farber Cancer Institute 2006-11-30
NCT00144677 Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00144677 Completed Dana-Farber Cancer Institute 2006-06-30
NCT00136474 Amifostine for Head and Neck Irradiation in Lymphoma https://ClinicalTrials.gov/show/NCT00136474 Completed Dana-Farber Cancer Institute 2005-05-31
NCT00134082 Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00134082 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2013-01-31
NCT00133367 Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus https://ClinicalTrials.gov/show/NCT00133367 Completed Massachusetts General Hospital 2007-11-30
NCT00132028 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00132028 Completed National Cancer Institute (NCI) 2009-05-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00117988 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00117988 Completed National Cancer Institute (NCI) 2010-04-30
NCT00113724 Study of TPI 287 in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT00113724 Completed Cortice Biosciences, Inc. 2008-01-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00090909 Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00090909 Completed Jonsson Comprehensive Cancer Center 2005-03-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00004169 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00004169 Completed Northwestern University 2007-01-31
NCT00003936 Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003936 Completed Barbara Ann Karmanos Cancer Institute 2004-06-30
NCT00002495 SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002495 Completed Southwest Oncology Group 2000-11-30
NCT00086801 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00086801 Completed Alliance for Clinical Trials in Oncology 2007-03-31
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00005578 Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00005578 Completed Children’s Oncology Group 2004-10-31
NCT00002827 Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002827 Completed Children’s Oncology Group 2004-10-31
NCT00002552 Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin’s Lymphoma, Hodgkin’s Disease, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00002552 Completed Barbara Ann Karmanos Cancer Institute 2001-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00082966 Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00082966 Completed National Cancer Institute (NCI) 2007-03-31
NCT00003849 Rituximab in Treating Patients With Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003849 Completed Alliance for Clinical Trials in Oncology 2005-02-28
NCT00002745 Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin’s Disease or Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00002745 Completed National Cancer Institute (NCI) 2003-04-30
NCT00004010 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00004010 Completed Children’s Oncology Group 2003-10-31
NCT00002714 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002714 Completed National Cancer Institute (NCI) NA
NCT00002461 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin’s Disease or Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00002461 Completed Montefiore Medical Center 1991-07-31
NCT00003421 Combination Chemotherapy in Treating Patients With Advanced Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003421 Completed National Cancer Institute (NCI) NA
NCT00079105 A Phase II Study VEPEMB In Patients With Hodgkin’s Lymphoma Aged ≥ 60 Years https://ClinicalTrials.gov/show/NCT00079105 Completed Newcastle-upon-Tyne Hospitals NHS Trust 2010-12-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00004908 Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin’s Disease or Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00004908 Completed Northwestern University 2002-06-30
NCT00004171 Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin’s Disease or Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00004171 Completed Northwestern University 2002-06-30
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00002561 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002561 Completed Canadian Cancer Trials Group 2011-08-15
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00003114 Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003114 Completed Case Comprehensive Cancer Center 2002-06-30
NCT00014209 Combination Chemotherapy in Hodgkin’s Disease or Non-Hodgkin’s Lymphoma Not Responding to Previous Treatment https://ClinicalTrials.gov/show/NCT00014209 Completed Canadian Cancer Trials Group 2002-07-15
NCT00062868 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma https://ClinicalTrials.gov/show/NCT00062868 Completed Baylor College of Medicine 2014-04-30
NCT00061672 Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00061672 Completed Abbott NA
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00060372 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer https://ClinicalTrials.gov/show/NCT00060372 Completed National Cancer Institute (NCI) 2008-04-30
NCT00058617 Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL https://ClinicalTrials.gov/show/NCT00058617 Completed Baylor College of Medicine 2011-08-31
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00027820 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00027820 Completed Fred Hutchinson Cancer Research Center 2004-09-30
NCT00025662 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS https://ClinicalTrials.gov/show/NCT00025662 Completed National Institutes of Health Clinical Center (CC) 2008-02-29
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00025259 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00025259 Completed Children’s Oncology Group 2012-08-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00005811 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment https://ClinicalTrials.gov/show/NCT00005811 Completed National Cancer Institute (NCI) 2006-04-30
NCT00005803 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00005803 Completed Fred Hutchinson Cancer Research Center 2016-01-31
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00003820 Rituximab in Treating Patients With Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00003820 Completed Stanford University 2008-08-31
NCT00003741 Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00003741 Completed National Cancer Institute (NCI) NA
NCT00051597 A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00051597 Completed Seattle Genetics, Inc. NA
NCT00039910 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia https://ClinicalTrials.gov/show/NCT00039910 Completed Pfizer NA
NCT00038558 Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin’s Disease Receiving ABVD Chemotherapy https://ClinicalTrials.gov/show/NCT00038558 Completed M.D. Anderson Cancer Center 2004-02-29
NCT00026208 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00026208 Completed Stanford University 2013-04-26
NCT00000626 Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00000626 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00165269 Mantle Irradiation for Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00165269 Completed Dana-Farber Cancer Institute 2000-06-30
NCT00001830 Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants https://ClinicalTrials.gov/show/NCT00001830 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001575 Anti-Tac(90 Y-HAT) to Treat Hodgkin’s Disease, Non-Hodgkin’s Lymphoma and Lymphoid Leukemia https://ClinicalTrials.gov/show/NCT00001575 Completed National Institutes of Health Clinical Center (CC) 2013-11-30
NCT00001430 A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas https://ClinicalTrials.gov/show/NCT00001430 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03361020 Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation https://ClinicalTrials.gov/show/NCT03361020 Recruiting St. Jude Children’s Research Hospital 2023-02-28
NCT03327571 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes https://ClinicalTrials.gov/show/NCT03327571 Completed Takeda 2019-10-31
NCT03260101 Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study https://ClinicalTrials.gov/show/NCT03260101 Recruiting Cellect Biotechnology 2021-12-31
NCT03200977 Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab https://ClinicalTrials.gov/show/NCT03200977 Recruiting Bristol-Myers Squibb 2022-12-30
NCT03161613 Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico https://ClinicalTrials.gov/show/NCT03161613 Recruiting Bristol-Myers Squibb 2019-04-01
NCT03042247 Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03042247 Recruiting Federico II University 2020-06-10
NCT02885038 Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies https://ClinicalTrials.gov/show/NCT02885038 Completed Etablissement Français du Sang 2016-03-31
NCT02856646 Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices https://ClinicalTrials.gov/show/NCT02856646 Recruiting Bristol-Myers Squibb 2023-09-28
NCT02795013 Genetic Study of Families With High Frequency of Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02795013 Completed St. Jude Children’s Research Hospital 2018-02-27
NCT02589548 Brazilian Prospective Hodgkin Lymphoma Registry https://ClinicalTrials.gov/show/NCT02589548 Recruiting Universidade Federal do Rio de Janeiro 2020-12-31
NCT01676805 Tissue Collection for Studies of Lymph Cancer https://ClinicalTrials.gov/show/NCT01676805 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00131014 Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00131014 Recruiting Dana-Farber Cancer Institute 2023-01-31
NCT00039676 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer https://ClinicalTrials.gov/show/NCT00039676 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02404818 Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy https://ClinicalTrials.gov/show/NCT02404818 Active, not recruiting University of Florida 2022-04-30
NCT02139592 Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” https://ClinicalTrials.gov/show/NCT02139592 Completed Takeda 2017-06-30
NCT02106611 Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors https://ClinicalTrials.gov/show/NCT02106611 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT02069639 TARC After alloSCT in Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02069639 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2014-01-31
NCT02057185 Occupational Status and Hematological Disease https://ClinicalTrials.gov/show/NCT02057185 Active, not recruiting Gruppo Italiano Malattie EMatologiche dell’Adulto 2019-03-31
NCT01820117 Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation https://ClinicalTrials.gov/show/NCT01820117 Completed St. Jude Children’s Research Hospital 2018-02-20
NCT01660776 BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology https://ClinicalTrials.gov/show/NCT01660776 Completed Rennes University Hospital 2017-10-02
NCT01505712 Biomarkers in Tissue Samples From Patients With Hodgkin Lymphoma Enrolled on ECOG-2496 Clinical Trial https://ClinicalTrials.gov/show/NCT01505712 Completed Eastern Cooperative Oncology Group 2012-11-19
NCT01490801 Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01490801 Completed Children’s Oncology Group 2016-05-31
NCT01478191 Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT https://ClinicalTrials.gov/show/NCT01478191 Completed Fondazione Italiana Linfomi ONLUS NA
NCT01459224 MELT - MRI Evaluation of Lymphoma Treatment https://ClinicalTrials.gov/show/NCT01459224 Completed University College, London 2014-09-30
NCT01366157 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01366157 Completed Children’s Oncology Group 2016-05-31
NCT04419441 Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04419441 Recruiting Ospedale Maggiore Di Trieste 2020-06-30
NCT04396119 Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study https://ClinicalTrials.gov/show/NCT04396119 Recruiting The Christie NHS Foundation Trust 2020-08-31
NCT04298619 Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission https://ClinicalTrials.gov/show/NCT04298619 Completed Federico II University 2016-04-30
NCT04028804 FLT PET: A Pilot Study in Lymphoma Patients https://ClinicalTrials.gov/show/NCT04028804 Completed The Hospital for Sick Children 2014-12-31
NCT03942263 A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation https://ClinicalTrials.gov/show/NCT03942263 Recruiting Takeda 2023-05-10
NCT03729609 Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Untreated CD30-Positive Hodgkin’s Lymphoma” https://ClinicalTrials.gov/show/NCT03729609 Recruiting Takeda 2022-05-31
NCT03664323 Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03664323 Completed Hospices Civils de Lyon 2018-01-31
NCT03535948 Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy https://ClinicalTrials.gov/show/NCT03535948 Active, not recruiting Central Hospital, Nancy, France 2019-11-30
NCT03469921 Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016 https://ClinicalTrials.gov/show/NCT03469921 Completed Institut Paoli-Calmettes 2016-12-31
NCT01248000 The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy https://ClinicalTrials.gov/show/NCT01248000 Completed Gruppo Italiano Studio Linfomi NA
NCT01228461 Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients https://ClinicalTrials.gov/show/NCT01228461 Completed Vanderbilt University Medical Center 2012-01-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01180010 Low Dose Chest Computed Tomography (CT) Screening https://ClinicalTrials.gov/show/NCT01180010 Completed University Health Network, Toronto 2015-09-30
NCT01141959 Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients https://ClinicalTrials.gov/show/NCT01141959 Completed Fred Hutchinson Cancer Research Center 2011-12-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01078350 Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy https://ClinicalTrials.gov/show/NCT01078350 Completed Stanford University 2015-12-04
NCT00924131 Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin’s Disease Previously Treated at NIH: A Multi-Institutional Trial https://ClinicalTrials.gov/show/NCT00924131 Completed National Institutes of Health Clinical Center (CC) NA
NCT00903890 Cardiac Effects in Long-Term Survivors of Hodgkin’s and Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00903890 Active, not recruiting University of Rochester 2018-11-30
NCT00900250 Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma https://ClinicalTrials.gov/show/NCT00900250 Completed Children’s Oncology Group 2019-03-31
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT03838627 Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR) https://ClinicalTrials.gov/show/NCT03838627 Completed St. Jude Children’s Research Hospital 2019-09-30
NCT04213209 Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma” https://ClinicalTrials.gov/show/NCT04213209 Recruiting Takeda 2022-12-31
NCT04005703 Whole-body MRI in Pediatric Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT04005703 Active, not recruiting UMC Utrecht 2016-12-31
NCT02682667 Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols https://ClinicalTrials.gov/show/NCT02682667 Recruiting National Institutes of Health Clinical Center (CC) 2025-12-01
NCT02378337 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality https://ClinicalTrials.gov/show/NCT02378337 Completed Hospital Sao Rafael 2015-08-31
NCT00764829 Blood Samples to Evaluate Biomarkers of Donor Chimerism https://ClinicalTrials.gov/show/NCT00764829 Completed Fred Hutchinson Cancer Research Center 2012-02-29
NCT00713882 Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors https://ClinicalTrials.gov/show/NCT00713882 Completed Weill Medical College of Cornell University 2008-11-30
NCT00685997 Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas https://ClinicalTrials.gov/show/NCT00685997 Completed UMC Utrecht 2012-01-31
NCT00608452 Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers https://ClinicalTrials.gov/show/NCT00608452 Completed Memorial Sloan Kettering Cancer Center 2009-11-30
NCT00598728 Quality of Life Among Survivors of Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00598728 Completed Memorial Sloan Kettering Cancer Center 2016-04-30
NCT00579917 Behavioral Intervention For BMT/SCT Survivors https://ClinicalTrials.gov/show/NCT00579917 Completed Memorial Sloan Kettering Cancer Center 2008-12-31
NCT00569842 Investigation of the Cylex® ImmuKnow® Assay https://ClinicalTrials.gov/show/NCT00569842 Completed Indiana University 2010-02-28
NCT00510315 Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00510315 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT00398177 Clinical and Pathologic Studies in Non-Hodgkin’s Lymphoma and Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00398177 Recruiting Stanford University 2099-01-31
NCT00386217 Psychosocial Impact of Cancer-Related Female Infertility https://ClinicalTrials.gov/show/NCT00386217 Completed M.D. Anderson Cancer Center 2008-11-30
NCT00301314 A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL). https://ClinicalTrials.gov/show/NCT00301314 Completed Royal Marsden NHS Foundation Trust NA
NCT00165438 Pulmonary Function in Patients With Hodgkin’s Disease Receiving Bleomycin-Based Chemotherapy https://ClinicalTrials.gov/show/NCT00165438 Completed Dana-Farber Cancer Institute 2005-11-30
NCT00165412 Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00165412 Completed Dana-Farber Cancer Institute 2010-05-31
NCT00002563 SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00002563 Completed Southwest Oncology Group 2003-09-30
NCT00006342 Genetic Study in Patients Receiving Treatment for Hodgkin’s Disease or Childhood Brain Tumor https://ClinicalTrials.gov/show/NCT00006342 Completed Duke University 2000-09-30
NCT00552825 Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children https://ClinicalTrials.gov/show/NCT00552825 Completed Sheba Medical Center NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03117036 Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III https://ClinicalTrials.gov/show/NCT03117036 Recruiting Samsung Medical Center 2022-02-28
NCT01904175 Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01904175 Completed Duke University 2016-04-30
NCT01890486 The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen https://ClinicalTrials.gov/show/NCT01890486 Recruiting Wake Forest University Health Sciences 2023-05-31
NCT03766516 Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL https://ClinicalTrials.gov/show/NCT03766516 Recruiting Samsung Medical Center 2020-06-30
NCT03440788 Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin’s Lymphoma Receiving Brentuximab Vedotin https://ClinicalTrials.gov/show/NCT03440788 Recruiting Multinational Center for Quality of Life Research, Russia 2020-05-01